Journal Based CME - Advances in Neoadjuvant and Adjuvant Immunotherapy and Targeted Therapy for Resectable NSCLC

Resectable non-small cell lung cancer (NSCLC) is currently treated with cisplatin-based adjuvant chemotherapy following surgical resection. Despite treatment with curative intent, there are high rates of disease recurrence with distant metastases, resulting in a 5-year mortality of 20-60%. Advances in immunotherapy (IO) in stage III and IV have led to improvements in overall survival. This journal-based accredited continuing education (CME) activity focuses on the advances in neoadjuvant and adjuvant immunotherapy and targeted therapy for resectable NSCLC. 

TO READ THE ARTICLE AND CLAIM CREDITS

Scroll down to the "Additional Information" tab to download & review the article. After reading the article, please return to this page to complete a quiz and activity evaluation to claim your CME credits!

The link to the article is also located on the program page and is hosted by the International Journal of Cancer Care and Delivery. 

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

The live portion of this activity and any associated enduring content has been supported with independent medical education grant(s) from the following companies:

  • Pfizer, Inc.
  • AstraZeneca
  • Regeneron
  • Exact Sciences
  • Jazz Pharmaceuticals

REGISTRATION FEES

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant. 

Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients

 

AVAILABLE CREDIT

1.00 ABIM MOC II

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
image

1.00 AMA PRA Category 1 Credit™

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Learning Objectives

Upon successful completion of this journal-based continuing education activity, participants will be able to:

  • Identify the recent advances in neoadjuvant and adjuvant immunotherapy and targeted therapy for resectable NSCLC
  • Discuss future studies on patient selection for either adjuvant or neoadjuvant therapy, role of IO alone, length of adjuvant treatment, and the role of circulating tumor DNA (ctDNA).

Additional Information

AttachmentSize
PDF icon Journal Article315.29 KB
Course summary
Available credit: 
  • 1.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 1.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Course opens: 
02/01/2022
Course expires: 
02/11/2023
Cost:
$1.00

This is a journal based continuing education activity. Please read the following article in the International Journal of Cancer Care and Delivery and login to your account on this site to claim credit.  "Advances in Neoadjuvant and Adjuvant Immunotherapy and Targeted Therapy for Resectable NSCLC" authored by Fares Alsawah, MD, and Dipesh Uprety, MD.

Link to article here.

After reading the article, please return to this page to complete a quiz and evaluation to claim your Continuing Education credits!

No members of this activity's planning committee or faculty have any relevant financial relationship with an ineligible entity except for the following faculties:

  • Dr. Upresh Diprety serves on the advisory board to Daiichi Sankyo and AstraZeneca.

All relevant financial relationships of individuals in control of the content have been identified and mitigated

Available Credit

  • 1.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 1.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Price

Cost:
$1.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.

 

CANCELLATION POLICY

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.

REFUND POLICY 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued.